Sumanta Chatterjee

AC air capacity ANN artificial neural network BD bulk density CRA climate resilient agriculture DL deep learning FC field capacity IGP Indo-Gangetic Plains KGML knowledge-guided machine KVK Krishi Vigyan Kendra MAE mean absolute error ML machine learning OLS ordinary least squares PDeff effective particle density PDmineral particle density of mineral matter PTF pedotransfer function PWP permanent wilting point RDG ridge regression RFR random forest regressor/random forest regression RMSE root...

Abstract Developing lung-targeting delivery systems is essential for treating pulmonary conditions such as genetic respiratory diseases, infections, fibrosis and cancer. We synthesized and evaluated 444 lung-targeting lipids (LuT lipids) that form lipid nanoparticles (LNPs) to efficiently deliver messenger RNA and CRISPR–Cas9 genome editors to lungs with minimal side effects.

Inhibition of disease-causing mutations using RNA interference (RNAi) has resulted in clinically approved medicines with additional candidates in late stage trials. However, targetable tissues currently in pre-clinical development are limited to liver following systemic intravenous (IV) administration because predictable delivery of siRNA to non-liver tissues remains an unsolved challenge.